Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of US oncologists
Kathryn F. Mileham et al.
CANCER MEDICINE (2022)
Computed tomography-guided lung biopsy for molecular tests: a meta-analysis
Jian-Hua Zhang et al.
KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2022)
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
Charu Aggarwal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
Mari Mino-Kenudson et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer
Adam H. Fox et al.
CHEST (2021)
Safety and Costs of Fndobronchial Ultrasound-Guided Nodal Aspiration and Mediastinoscopy
Francys C. Verdial et al.
CHEST (2020)
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Sylvie Lantuejoul et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T. Mok et al.
ANNALS OF ONCOLOGY (2020)
Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma
Kartik Anand et al.
CLINICAL LUNG CANCER (2020)
The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer
Matthew P. Smeltzer et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2020)
Epidemiology of Brain Metastases
Patricia Sacks et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations
Andreanne Gagne et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics
Lena Boenig et al.
FRONTIERS IN NEUROLOGY (2019)
Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer
Kenneth L. Kehl et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sensitivity of Initial Thoracentesis for Malignant Pleural Effusion Stratified by Tumor Type in Patients with Strong Evidence of Metastatic Disease
Horiana B. Grosu et al.
RESPIRATION (2018)
Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions
Kathryn A. Phillips et al.
VALUE IN HEALTH (2018)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Endobronchial ultrasound-guided transbronchial needle aspiration: Safe as it sounds
Preyas J. Vaidya et al.
RESPIROLOGY (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
The Eighth Edition Lung Cancer Stage Classification
Frank C. Detterbeck et al.
CHEST (2017)
Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer
Willemijne A. M. E. Schrijver et al.
MODERN PATHOLOGY (2016)
Etiology of Pleural Effusions: Analysis of More than 3,000 Consecutive Thoracenteses
Jose M. Porcel et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2014)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)